Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents

References

• CitromeLAgitation III: pharmacologic treatment of agitationGlickRLBerlinJSFishkindABZellerSLEmergency Psychiatry: Principles and PracticeBaltimore, MDLippincott Williams and Wilkins2008137148
   Google Scholar
• CitromeLVolavkaJViolent patients in the emergency settingPsychiatr Clin North Am199922478980110623971
   PubMed Web of Science ®Google Scholar
• NolanKAShopeCBCitromeLVolavkaJStaff and patient views of the reasons for aggressive incidents: a prospective, incident-based studyPsychiatr Q200980316717219412665
   PubMed Web of Science ®Google Scholar
• NolanKAVolavkaJCzoborPAggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorderJ Psychiatr Res200539110911515504429
   PubMed Web of Science ®Google Scholar
• NolanKACzoborPRoyBBCharacteristics of assaultive behavior among psychiatric inpatientsPsychiatr Serv20035471012101612851439
   PubMed Web of Science ®Google Scholar
• VolavkaJCitromeLPathways to aggression in schizophrenia affect results of treatmentSchizophr Bull201137592192921562140
   PubMed Web of Science ®Google Scholar
• VolavkaJCitromeLHeterogeneity of violence in schizophrenia and implications for long-term treatmentInt J Clin Pract20086281237124518564202
   PubMed Web of Science ®Google Scholar
• AdvokatCA brief overview of iatrogenic akathisiaClin Schizophr Relat Psychoses201034226236
   Google Scholar
• CitromeLKrakowskiMGreenbergWMAndradeEVolavkaJAntiaggressive effect of quetiapine in a patient with schizoaffective disorderJ Clin Psychiatry2001621190111775051
   PubMed Web of Science ®Google Scholar
• CitromeLGreenLThe dangerous agitated patient. What to do right nowPostgrad Med19908722312362405373
   PubMed Web of Science ®Google Scholar
• CitromeLVolavkaJClinical management of persistent aggressive behavior in schizophrenia. Part I: definitions, epidemiology, assessment, and acute treatmentEssent Psychopharmacol200251116
   Google Scholar
• AhmedUJonesHAdamsCEChlorpromazine for psychosis induced aggression or agitation [review]Cochrane Database Syst Rev20104CD00744520393959
   PubMed Web of Science ®Google Scholar
• PowneyMJAdamsCEJonesHHaloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [review]Cochrane Database Syst Rev201211CD00937723152276
   PubMed Web of Science ®Google Scholar
• CitromeLLimited evidence on effects of haloperidol alone for rapid tranquillisation in psychosis-induced aggressionEvid Based Ment Health20131624723416523
   PubMedGoogle Scholar
• VinogradovSFisherMWarmHHollandCKirshnerMAPollockBGThe cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophreniaAm J Psychiatry200916691055106219570929
   PubMed Web of Science ®Google Scholar
• CitromeLComparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safetyJ Clin Psychiatry200768121876188518162018
   PubMed Web of Science ®Google Scholar
• WilsonMPPepperDCurrierGWHollomanGHJrFeifelDThe psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology workgroupWest J Emerg Med2012131263422461918
   PubMedGoogle Scholar
• US Food and Drug AdministrationNDA Approval Letter, December 21, 2012Silver Spring, MDUS Food and Drug Administration2012 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022549Orig1s000ltr.pdfAccessed March 17, 2013
   Google Scholar
• Adasuve^®(loxapine) inhalation powder, for oral inhalation use [prescribing information]Mountain View, CAAlexza Pharmaceuticals2012
   Google Scholar
• Alexza PharmaceuticalsAlexza receives marketing authorization for Adasuve^®(Staccato^®loxapine) in the European Union [press release]Mountain View, CAAlexza Pharmaceuticals2013 Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=196151&p=irol-newsArticle&ID=1787494Accessed March 17, 2013
   Google Scholar
• Adasuve^®: summary of product characteristics [webpage on the Internet]Mountain View, CAAlexza Pharmaceuticals2012 Available from: http://www.adasuve.com/index-eu.phpAccessed March 17, 2013
   Google Scholar
• AllenMHFeifelDLesemMDEfficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trialJ Clin Psychiatry201172101313132121294997
   PubMed Web of Science ®Google Scholar
• LesemMDTran-JohnsonTKRiesenbergRARapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapineBr J Psychiatry20111981515821200077
   PubMed Web of Science ®Google Scholar
• KwentusJRiesenbergRAMarandiMRapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapineBipolar Disord2012141314022329470
   PubMed Web of Science ®Google Scholar
• Alexza PharmaceuticalsAdasuve^®(Loxapine) Inhalation Powder NDA 022549: Psychopharmacologic Drug Advisory Committee Briefing DocumentMountain View, CAAlexza Pharmaceuticals2011 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM282900.pdfAccessed March 19, 2013
   Google Scholar
• US Food and Drug AdministrationAdasuve^®(Loxapine) Inhalation Powder NDA 022549: Psychopharmacologic Drug Advisory Committee Briefing DocumentSilver Spring, MDUS Food and Drug Administration2011 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM282897.pdfAccessed March 19, 2013
   Google Scholar
• European Medicines AgencyAdasuve^®Assessment ReportLondonEuropean Medicines Agency2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002400/WC500139407.pdfAccessed March 17, 2013
   Google Scholar
• CitromeLAerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorderInt J Clin Pract201165333034021199198
   PubMed Web of Science ®Google Scholar
• CitromeLInhaled loxapine for agitation revisited: focus on effect sizes from two Phase III randomised controlled trials in persons with schizophrenia or bipolar disorderInt J Clin Pract201266331832522226343
   PubMed Web of Science ®Google Scholar
• NoymerPMyersDGlazerMFishmanRSCassellaJVThe Staccato® system: inhaler design characteristics for rapid treatment of CNS disordersRespiratory Drug Delivery201011120
   Google Scholar
• DinhKMyersDJGlazerMIn vitro aerosol characterization of Staccato® loxapineInt J Pharm20114031–210110820971174
   PubMed Web of Science ®Google Scholar
• DinhKVMyersDJNoymerPDCassellaJVIn vitro aerosol deposition in the oropharyngeal region for Staccato® loxapineJ Aerosol Med Pulm Drug Deliv201023425326020528148
   PubMed Web of Science ®Google Scholar
• EreshefskyLPharmacologic and pharmacokinetic considerations in choosing an antipsychoticJ Clin Psychiatry199960Suppl 10203010340684
   PubMed Web of Science ®Google Scholar
• SpykerDAMunzarPCassellaJVPharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteersJ Clin Pharmacol201050216917919915181
   PubMed Web of Science ®Google Scholar
• Amoxapine tablet drug label [webpage on the Internet]Bethesda, MDNational Institute of Health2010 Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=19651Accessed November 12, 2010
   Google Scholar
• CitromeLCompelling or irrelevant? Using number needed to treat can help decideActa Psychiatr Scand2008117641241918479317
   PubMed Web of Science ®Google Scholar
• CassellaJSpykerDKwentusJLesemMFishmanRRapid improvement in the five-item Positive and Negative Syndrome – Excited Component (PANSS-EC) scale for agitation with inhaled loxapine50th Meeting of the NCDEUJune 14–17, 2010Boca Raton, FL, USA
   Google Scholar
• CitromeLQuantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medicationsCurr Drug Saf20094322923719534647
   PubMedGoogle Scholar
• US Food and Drug AdministrationAdasuve^®(loxapine) Inhalation Powder: Risk Evaluation and Mitigation StrategySilver Spring, MDUS Food and Drug Administration2012 Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM333242.pdfAccessed March 17, 2013
   Google Scholar
• CitromeLNasrallahHAOn-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does notExpert Opin Pharmacother201213111599161322017361
   PubMed Web of Science ®Google Scholar
• CitromeLEvidence-based medicine: it’s not just about the evidenceInt J Clin Pract201165663463521564431
   PubMed Web of Science ®Google Scholar